Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Warnke, PH; Humpe, A; Strunk, D; Stephens, S; Warnke, F; Wiltfang, J; Schallmoser, K; Alamein, M; Bourke, R; Heiner, P; Liu, Q.
A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies.
J Craniomaxillofac Surg. 2013; 41(2):153-161
Doi: 10.1016/j.jcms.2012.07.003
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Schallmoser Katharina
-
Strunk Dirk
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The transplantation of human stem cells seeded on biomaterials holds promise for many clinical applications in cranio-maxillo-facial tissue engineering and regenerative medicine. However, stem cell propagation necessary to produce sufficient cell numbers currently utilizes fetal calf serum (FCS) as a growth supplement which may subsequently transmit animal pathogens. Human platelet lysate (HPL) could potentially be utilized to produce clinical-grade stem cell-loaded biomaterials as an appropriate FCS substitute that is in line with clinically-applicable practice. The goal of this study was to investigate whether HPL can be successfully used to propagate human mesenchymal stem cells (HMSCs) seeded on clinically-approved collagen materials under clinically-applicable conditions using FCS as a control. HMSCs were isolated from bone marrow and cultured in the presence of 10% FCS or 10% HPL. Characterization of HMSCs was performed by flow cytometry and through osteogenic and adipogenic differentiation assays. Proliferative capacity of HMSCs on both matrices was investigated by mitochondrial dehydrogenase assays (WST) and tissue coverage scanning electron microscopy (SEM). The isolated HMSC differentiated into osteogenic and adipogenic cells authenticating the multipotentiality of the HMSCs. WST tests and the SEM images demonstrated that HPL was generally superior to FCS in promoting growth of seeded HMSCs. For all other tests HPL supported HMSCs at least equal to FCS. In conclusion, HPL is an effective growth factor to allow expansion of clinical-grade HMSCs on clinically-approved biomaterials for maxillofacial and oral implantology applications.
- Find related publications in this database (using NLM MeSH Indexing)
-
Adipogenesis - physiology
-
Biocompatible Materials - chemistry
-
Blood -
-
Blood Platelets - chemistry
-
Bone Marrow Cells - physiology
-
Cell Culture Techniques -
-
Cell Differentiation - physiology
-
Cell Lineage - physiology
-
Cell Proliferation -
-
Cell Survival - physiology
-
Collagen - chemistry
-
Feasibility Studies -
-
Flow Cytometry -
-
Fluorescein-5-isothiocyanate - diagnostic use
-
Fluorescent Dyes - diagnostic use
-
Formazans - diagnostic use
-
Humans -
-
Intercellular Signaling Peptides and Proteins - therapeutic use
-
Male -
-
Mesenchymal Stromal Cells - physiology
-
Microscopy, Electron, Scanning -
-
Middle Aged -
-
Multipotent Stem Cells - physiology
-
Osteogenesis - physiology
-
Regeneration - physiology
-
Tetrazolium Salts - diagnostic use
-
Time Factors -
-
Tissue Scaffolds - chemistry
- Find related publications in this database (Keywords)
-
Human mesenchymal stem cells
-
MSC
-
Tissue engineering
-
Clinically-applicable practice
-
Regenerative
-
Regeneration
-
FCS
-
Stem cell
-
Translational
-
Protocol